Newly approved drug effective against lung cancer caused by genetic mutation (VIDEO)

WashU Medicine

Caption

Medical oncologist and senior author of a new lung cancer study, Ramaswamy Govindan, MD, of Washington University School of Medicine in St. Louis, talks about the newly FDA-approved drug sotorasib. The new study shows that sotorasib benefits some patients who have non-small-cell lung cancer that has a specific mutation in the KRAS gene. Ongoing clinical trials for lung cancer patients are investigating combinations of sotorasib plus other experimental drugs.

Credit

Huy Mach/Washington University School of Medicine in St. Louis

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.